Zymeworks Inc. Common Shares (ZYME) Social Stream
Zymeworks Inc (ZYME) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ZYME.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-04 | 8 | $74 | $28 | $48.875 | $6.66 | 633.86% |
| 2021-11-10 | 8 | $74 | $27 | $48.75 | $6.66 | 631.98% |
| 2021-11-17 | 9 | $74 | $27 | $47.875 | $6.66 | 618.84% |
| 2021-12-10 | 9 | $74 | $27 | $47.875 | $6.66 | 618.84% |
| 2021-12-14 | 9 | $74 | $27 | $45.375 | $6.66 | 581.31% |
| 2022-01-24 | 9 | $51 | $27 | $40.857 | $6.66 | 513.47% |
| 2022-02-01 | 8 | $51 | $27 | $37.571 | $6.66 | 464.13% |
| 2022-02-24 | 8 | $51 | $18 | $34.714 | $6.66 | 421.23% |
| 2022-03-15 | 9 | $44 | $15 | $28.875 | $6.66 | 333.56% |
The Trend in the Analyst Price Target
ZYME's average price target has moved down $20 over the prior 131 days.
ZYME reports an average of 262.95% for its upside potential over the past 131 days.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-17 | 9 | 74 | 27 | 47.875 | 19.58 | 144.51% |
| 2021-12-10 | 9 | 74 | 27 | 47.875 | 16.07 | 197.92% |
| 2021-12-14 | 9 | 74 | 27 | 45.375 | 15.91 | 185.2% |
| 2022-01-24 | 8 | 51 | 27 | 40.857 | 10.00 | 308.57% |
| 2022-02-01 | 8 | 51 | 27 | 36.000 | 8.41 | 328.06% |
ZYME Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.78 | 5 | 1 | 3 | 0 | 0 | 9 |
The Trend in the Broker Recommendations
ZYME's average broker recommendation rating improved by 0.22 over the prior 120 days.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- Zymeworks Inc's upside potential (average analyst target price relative to current price) is higher than 1056.21% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, Zymeworks Inc's variance in analysts' estimates is lower than -843.49% of them.
- In the context of Pharmaceutical Products stocks, Zymeworks Inc's number of analysts covering the stock is greater than 789.13% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Zymeworks Inc's average analyst price target is greater than 671.69% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Zymeworks Inc are ZNTL, YMAB, and XNCR.
Make investment decisions regarding ZYME using the data that counts. Try POWR Ratings for free.